PMVP · PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals continued to report operating losses in Q1 FY2026, though the operating loss narrowed 11.8% to -$19.0 million from -$21.6 million in the prior-year quarter. This improvement reflects disciplined cost management amid ongoing advancement of rezatapopt, the company's lead candidate, even as resources remain primarily directed toward research and development expenditures. The company expenses R&D costs as incurred, aligning with its strategy to fund operating expenses through available capital.

Net income reflected a 3.5% widening of losses to -$18.0 million compared to -$17.4 million last year, driven by the exhaustion of one-time NJ tax credit benefits received in Q1 2025. Diluted EPS remained stable at -$0.34 year-over-year, indicating consistent per-share loss dynamics despite the net income shift. These results underscore the clinical-stage biotech's focus on development milestones over near-term profitability, with operating performance showing modest resilience.

Cash flow from operations accelerated negatively to -$19.7 million from -$18.3 million prior year, primarily due to changes in net operating assets and liabilities. Management noted these shifts stemmed from decreases in prepaid expenses and other assets, alongside decreases in outstanding payables and accrued expenses, creating working capital headwinds. With no capital expenditures this quarter (down from $4 thousand last year), free cash flow mirrored operating cash flow at -$19.7 million. This burn rate supports the company's plan of operation, channeling capital primarily into R&D to progress rezatapopt toward key milestones.